Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades ResMed to Neutral

JP Morgan Downgrades ResMed to Neutral

JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.

byBenzinga Newsdesk

August 12, 2022

1 minute read

JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.

Sprite Tells Consumers To ‘Obey Your Thirst’ In Clear Bottle, As It Ditches Signature Green Bottle: Why It Matters

By AJ Fabino

July 28, 1:28 PM

Get ready to say goodbye to the iconic green bottle.

News

Reported Late Tuesday, FTAC Zeus Acquisition Corp. Announces Change Of Special Meeting Date; Being Postponed To Wednesday, December 21, 2022

By Benzinga Newsdesk

December 14, 1:56 AM

FTAC Zeus Acquisition Corp.

ZING

Needham Previews Neurocrine’s Upcoming Mid-Stage Data from Essential Tremor Study

By Vandana Singh

July 11, 2:20 PM

Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.

JAZZ

News

Why AdvisorShares Pure US Cannabis ETF (MSOS) Is Up 67% Over The Past Week

By Henry Khederian

September 5, 3:12 PM

AdvisorShares Pure US Cannabis ETF (NASDAQ: MSOS) shares are trading higher by 67% to $8.13 over the trailing week, driven by the recent, strong performance of the cannabis sector.

MSOS

JP Morgan Downgrades ResMed to Neutral

Related Posts

Sprite Tells Consumers To ‘Obey Your Thirst’ In Clear Bottle, As It Ditches Signature Green Bottle: Why It Matters

Reported Late Tuesday, FTAC Zeus Acquisition Corp. Announces Change Of Special Meeting Date; Being Postponed To Wednesday, December 21, 2022

Needham Previews Neurocrine’s Upcoming Mid-Stage Data from Essential Tremor Study

Why AdvisorShares Pure US Cannabis ETF (MSOS) Is Up 67% Over The Past Week